- Accretropin brand name
- Accretropin dosage
- Accretropin dosage forms
- Accretropin adult dose
- Accretropin mg
- Accretropin drug
- Accretropin effects of
- Accretropin adverse effects
- Accretropin injection
Commonly used brand name(s)
In the U.S.
- Genotropin Miniquick
- Norditropin Flexpro
- Nutropin AQ NuSpin 10
- Nutropin AQ NuSpin 5
- Nutropin AQ Pen
- Nutropin Aq
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Endocrine-Metabolic Agent
Pharmacologic Class: Somatropin
Uses For Accretropin
Somatropin is a man-made version of human growth hormone. Growth hormone is naturally produced by the pituitary gland and is necessary to stimulate growth in children. Man-made growth hormone may be used in adults or children who have certain conditions that prevent normal growth. These conditions include growth hormone deficiency (inability to produce enough growth hormone), chronic kidney disease, idiopathic short stature (unexplained shortness), Noonan syndrome, Turner syndrome, short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years of age.
This medicine is available only with your doctor's prescription.
Usual Adult Dose for Cachexia
0.1 mg/kg subcutaneously once a day at bedtime
Under 35 kg/ 75 lbs: 0.1 mg/kg subcutaneously once a day at bedtime
35 to 45 kg/ 75 to 99 lbs: 4 mg subcutaneously once a day at bedtime
45 to 55 kg/ 99 to 121 lbs: 5 mg subcutaneously once a day at bedtime
Over 55 kg/ 121 lbs: 6 mg subcutaneously once a day at bedtime
Maximum dose: 6 mg once a day
-Most of the effect on work output and lean body mass were seen after 12 weeks of treatment.
-There are no data on safety or efficacy with use beyond 48 weeks.
-There are no data on safety or efficacy of intermittent treatment.
Use: Treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance.
Somatropin Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited data indicate that exogenous somatropin does not increase normal breastmilk concentrations of growth hormone and that no adverse effects are experienced by the breastfed infants of mothers who receive somatropin. Small studies by one group of investigators found that milk output increases from 19 to 36% after a 7-day course of somatropin. Because mothers were not given extensive breastfeeding support in these studies, the usefulness of the drug as a galactoogue in mothers given adequate breastfeeding support is not known. Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production.
Maternal Levels. Eight lactating women were given somatropin 0.1 international units/kg daily subcutaneously for 7 days. There was no difference in human growth hormone concentrations in breastmilk before and 1 day after finishing the course of somatoropin. Milk concentration of insulin-like growth factor-1 (IGF-I) increased by 91% from 1.04 to 1.99 mcg/L over the same time period. In a study of similar design, the same group of investigators reported an increase of 134% in IGF-I over the study period. There was no change in milk concentrations of IGF-II during the study.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Among 34 infants in 3 studies who were breastfed during maternal use of subcutaneous somatropin for 7 days during lactation, none were reported to have adverse reactions to the drug. Dosages were 0.05 (n = 5), 0.1 (n = 13) or 0.2 (n = 16) international units daily.
Effects on Lactation and Breastmilk
In a double-blind study, normal, lactating women were given somatropin 0.1 international units/kg daily subcutaneously for 7 days or placebo. The 8 women given somatropin increased their average milk output by 157 mL daily from the baseline of 835 mL daily. Placebo-treated patients experienced an increase from 855 mL daily to 955 mL daily. The difference in increase between the two groups was statistically significant. Milk content did not change with therapy.
Ten mothers of premature infants born at an average of 30.6 weeks gestation (range 26 to 34 weeks) were given subcutaneous somatropin to increase their milk supply at an average of 39.7 days postpartum. The dosage was 0.2 international units daily, up to a maximum of 16 international units daily, for 7 days. The amount of milk produced on day 8 was compared to the average amount extracted on the 2 days prior to therapy. Average milk production increased from 139 mL daily to 175 mL daily compared to a statistically nonsignificant increase from 93 mL daily to 102 mL daily in the placebo group. Many of the mothers in the placebo group, but none in the somatropin group, had decreases in production during the study. The differences in baseline milk production between the 2 groups might have affected the response to somatropin and the study did not report the changes, if any, in the proportion of infant nutrition from breastmilk.
The same group studied 16 lactating mothers with normal healthy infants; 5 of the women were having lactational problems. Women received either subcutaneous somatropin 0.05, 0.1 or 0.2 international units daily for 7 days. The two low-dose groups (n = 10) had a 4.7% increase in their milk output; mothers in the high-dose group (n = 6) increased their milk output by 36% from the baseline of 297 mL daily output. Three of the mothers who received the higher dose were able to completely or nearly completely breastfeed their infants.
None of the above studies reported providing mothers with information on breastfeeding technique or any other type of breastfeeding support. In a study designed to determine the genetic effects of growth hormone administration, 5 nursing mothers were given somatropin (Nortitropin) 0.1 mg/kg by subcutaneous injection once daily at about 800 am for 3 days. No difference was found in the average suckling-induced serum prolactin levels on day 1 (baseline) and day 4. Average milk volume did not change over the 4-day study period. The study found that DNA synthesis and cell cycle genes were induced, but no changes were observed in the expression of milk synthesis genes. The authors speculated that the duration of the study might have been too short to observe induction of milk synthesis genes.
1. The Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First revision January 2011). Breastfeed Med. 2011;6:41-9. PMID: 21332371
2. Milsom SR, Breier BH, Gallaher BW et al. Growth hormone stimulates galactopoiesis in healthy lactating women. Acta Endocrinol (Copenh). 1992;127:337-43. PMID: 1449045
3. Breier BH, Milsom SR, Blum WF et al. Insulin-like growth factors and their binding proteins in plasma and milk after growth hormone-stimulated galactopoiesis in normally lactating women. Acta Endocrinol (Copenh). 1993;129:427-35. PMID: 7506471
4. Milsom SR, Rabone DL, Gunn AJ, Gluckman PD. Potential role for growth hormone in human lactation insufficiency. Horm Res. 1998;50:147-50. PMID: 9762002
5. Gunn AJ, Gunn TR, Rabone DL et al. Growth hormone increases breast milk volumes in mothers of preterm infants. Pediatrics. 1996;98 (2 pt 1):279-82. PMID: 8692630
6. Maningat PD, Sen P, Rijnkels M et al. Short-term administration of rhGH increases markers of cellular proliferation but not milk protein gene expression in normal lactating women. Physiol Genomics. 2011;43:381-91. PMID: 21205870